Why the study?
Does rosiglitazone improve resting and post-occlusive forearm blood flow in patients with type 2 diabetes?
Does rosiglitazone improve resting and post-occlusive forearm blood flow in patients with type 2 diabetes?
Rosiglitazone improves vascular reactivity and endothelial function in patients with type 2 diabetes, restoring post-occlusive forearm blood flow to levels comparable to age-matched controls.
No takes yet. Share an insight, caveat, or question.
May normalize post-occlusive flow in T2D; hypothesis-generating and should not yet change practice.
Petrofsky et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: